BindingDB logo
myBDB logout

282 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28337319 28 Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.EBI Universit£ di Pisa
27914947 11 Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs).EBI University of Florence
27825552 152 Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.EBI Takeda Pharmaceutical Company Limited
27452283 241 Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.EBI Jadavpur University
27038494 18 Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.EBI Fudan University
27039251 66 Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors.EBI Shandong University
26871660 68 Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.EBI San Raffaele Scientific Institute
26653735 81 Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI Pfizer Inc.
26753813 22 Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI University of Minnesota
26638045 58 Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.EBI UiT The Arctic University of Norway
26346367 77 Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.EBI Nanjing University
26386821 15 Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.EBI Shandong University
26263024 47 N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.EBI Universit£ di Pisa
26192023 71 SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.EBI £Florida Atlantic University
25264600 64 Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI Takeda Pharmaceutical Company Limited
25921268 36 New matrix metalloproteinase inhibitors based on┐-fluorinateda-aminocarboxylic anda-aminohydroxamic acids.EBI Westf£lische Wilhelms-Universit£t M£nster
25438884 11 A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [╣8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.EBI University Medical Center Groningen
25415648 63 Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.EBI Eli Lilly and Company
25265401 38 Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.EBI Universidad CEU San Pablo
25192810 66 Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1┐ binding site.EBI Takeda Pharmaceutical Company Ltd
24813742 98 Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.EBI Universit£ degli Studi
24755524 60 Design, synthesis and preliminary evaluation ofa-sulfonyl┐-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.EBI Shandong University
24028490 46 O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.EBI University of Notre Dame
23453070 42 A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.EBI Asahi Kasei Pharma Corporation
23376997 53 Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.EBI Universit£ di Pisa
23375794 220 Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.EBI Nanjing University of Chinese Medicine
23353736 41 Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).EBI Second Military Medical University
23287054 46 Sulphonamides: Deserving class as MMP inhibitors?EBI Indian Institute of Technology (BHU)
23458498 24 Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.EBI Universit£ del Piemonte Orientale"Amedeo Avogadro"
23246356 52 MMP inhibition by barbiturate homodimers.EBI Trinity College
17275314 701 Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.EBI Pomona College
21669521 44 Selective non zinc binding inhibitors of MMP13.EBI AstraZeneca
23134659 74 Design and synthesis of procollagen C-proteinase inhibitors.EBI FibroGen Inc.
22894736 99 Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment.EBI The Hebrew University of Jerusalem
21780776 40 Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI Wroclaw University of Technology
21413800 56 A one-pot synthesis and biological activity of ageladine A and analogues.EBI Macquarie University
23149299 50 Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.EBI Universit£ degli Studi di Bari Aldo Moro
22967811 62 Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.EBI Tianjin Medical University
22540974 67 A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.EBI University Hospital M£nster
22248361 24 Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.EBI Trinity College
22658537 76 Natural products as a gold mine for selective matrix metalloproteinases inhibitors.EBI East China University of Science and Technology
22175799 22 Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI Alantos Pharmaceuticals AG
22607877 38 Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.EBI Shandong University
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
19635666 119 Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.EBI Incyte Corporation
19339187 49 Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II).EBI Shandong University
19329328 42 Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I).EBI Shandong University
19095454 63 Current perspective of TACE inhibitors: a review.EBI The M. S. University of Baroda
17981034 51 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.EBI Johnson& Johnson Pharmaceutical Research and Development
18053726 364 Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI Johnson& Johnson Pharmaceutical Research& Development
17980583 46 Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).EBI Johnson& Johnson Pharmaceutical Research and Development
18086526 85 beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.EBI Johnson& Johnson Pharmaceutical Research and Development
18257543 16 Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.EBI The Hebrew University of Jerusalem
18251495 69 Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
18061445 103 Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Research and Development
18029173 316 Synthesis and evaluation of novel heterocyclic MMP inhibitors.EBI North Dakota State University
17956082 86 Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.EBI University Hospital of the Westf£lische Wilhelms-Universit£t M£nster
17127067 21 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.EBI Instituto Superior T£cnico
17276072 95 Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.EBI Universit£ di Pisa
15857146 30 C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.EBI University Hospital of the Westf£lische Wilhelms-Universit£t
15713379 40 N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.EBI Universit£ degli Studi di Pisa
15582436 7 N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.EBI Sejong University
15139760 110 Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.EBI The Hebrew University of Jerusalem
12930146 170 Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.EBI Institut de Recherches Servier
12773042 195 Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
11472217 157 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI DuPont Pharmaceuticals Company
11472202 143 Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.EBI TBA
10669559 180 Protease inhibitors: current status and future prospects.EBI University of Queensland
10649971 180 Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.EBI Parke-Davis Pharmaceutical Research
10579818 162 Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
9888835 42 Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.EBI Procter and Gamble Pharmaceuticals
1322986 13 Inhibition of collagenase by aranciamycin and aranciamycin derivatives.EBI Technical University of Denmark
14980648 16 New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.EBI Universit£ des Sciences et Technologies de Lille
15177439 96 Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.EBI Pfizer Inc.
12824028 75 Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.EBI Pfizer Inc.
11327577 86 Heterocycle-based MMP inhibitors with P2' substituents.EBI Procter and Gamble Pharmaceuticals
11591510 54 alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.EBI Pfizer Inc.
11378378 34 Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.EBI Celltech Chiroscience Ltd
11133099 43 Synthesis and activity of selective MMP inhibitors with an aryl backbone.EBI Pharmacia
10450979 4 Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.EBI University of Cambridge
10397503 40 Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.EBI Universit£ de Montr£al
22386984 67 In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.EBI Colosseum Combinatorial Chemistry Centre for Technology (C4T SCarl)
22175825 19 Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI Pfizer Inc.
22118188 50 A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.EBI University Hospital M£nster
22153941 140 Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.EBI AstraZeneca
22017539 75 Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI Boehringer Ingelheim Pharmaceuticals Inc
22017477 35 Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI Instituto Superior T£cnico
22153340 37 Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).EBI Pfizer Inc.
22082667 67 Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.EBI Microbiotix, Inc.
22088955 33 Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.EBI Universit£ di Napoli Federico II Via D. Montesano 49
21937229 82 Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.EBI Novartis Institutes for Biomedical Research
21925881 60 Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.EBI Johnson& Johnson Pharmaceutical Research& Development
21866961 28 Selective water-soluble gelatinase inhibitor prodrugs.EBI University of Notre Dame
21911297 40 Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.EBI Shan Dong University
21802307 64 Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.EBI Shandong University
21764590 98 N-substituted homopiperazine barbiturates as gelatinase inhibitors.EBI Trinity College
20726512 282 Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.EBI Pfizer Inc.
21514700 56 Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.EBI Universit£ di Pisa
21536437 219 Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.EBI AstraZeneca
20638281 56 Structure and activity relationships of tartrate-based TACE inhibitors.EBI Merck Research Laboratories
21507637 102 MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.EBI Pfizer Inc.
21493063 67 MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.EBI Pfizer Inc.
21458257 87 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI Merck Research Laboratories
21300546 129 The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.EBI AstraZeneca
21189019 22 Identifying chelators for metalloprotein inhibitors using a fragment-based approach.EBI University of California
20970895 4 2-Azetidinone--a new profile of various pharmacological activities.EBI Barkatullah University
21106451 39 Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI Merck Research Laboratories
20637634 48 Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.EBI Shandong University
20529685 70 MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.EBI Pfizer Research& Development
20529684 112 Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.EBI Pfizer Research& Development
20180536 128 Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI Universit£ di Pisa
20172725 49 Discovery and SAR of hydantoin TACE inhibitors.EBI Merck Research Laboratories
20053563 10 Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.EBI Wonkwang University Sanbon Medical Center
20022498 71 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Schering-Plough Research Institute Cambridge
19969464 56 Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors.EBI Shandong University
20097082 20 Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I).EBI Shandong University
20005097 58 Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
19948404 1 Synthesis and anticancer activities of ageladine A and structural analogs.EBI Beckman Research Institute at City of Hope
19782572 62 Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13.EBI Shandong University
19703773 63 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI GSK Medicines Research Centre
19775099 184 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.EBI Universit£ di Pisa
19454370 52 Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.EBI Shandong University
19625186 59 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.EBI Wyeth Research
19524436 27 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.EBI University of Shizuoka and Global COE Program
19725580 93 Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI Wyeth Research
19606871 124 N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.EBI Universit£ di Pisa
18835710 69 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI Schering Plough Research Institute
 2 Synthesis of conformationally constrained potential inhibitors of mammalian metalloproteinasesEBI TBA
 96 Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocketEBI TBA
 30 Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimicsEBI TBA
 30 Orally active inhibitors of stromelysin-1 (MMP-3)EBI TBA
 60 Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptidesEBI TBA
 49 Phosphinic acid inhibitors of matrix metalloproteinasesEBI TBA
 18 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'EBI TBA
 66 Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalaninesEBI TBA
 40 Novel indolactam-based inhibitors of matrix metalloproteinasesEBI TBA
 60 Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivativesEBI TBA
 76 Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivativesEBI TBA
19457660 90 Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.EBI Incyte Corporation
19410464 71 Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.EBI Wyeth Research
19329309 49 Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.EBI Wyeth Research
19261472 16 Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.EBI University of California
19053764 101 Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.EBI Instituto Superior Técnico
18996018 42 Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN).EBI Shandong University
18945617 50 Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI Pfizer Global Research and Development
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18782669 90 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.EBI Université de Reims-Champagne-Ardenne
18718763 50 Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.EBI Shandong University
18571419 24 Novel aminopeptidase N inhibitors derived from 1,3,4-thiadiazole scaffold.EBI ShanDong University
18467109 21 Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors.EBI Shandong University
18440232 38 Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.EBI Shandong University
18362041 59 Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors.EBI Shandong University
17719700 39 Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.EBI Università G. d'Annunzio
17623656 34 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.EBI Pfizer Global Research and Development
18083558 112 beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.EBI Johnson & Johnson Pharmaceutical Research and Development
18068976 132 Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.EBI Incyte Corporation
18036818 157 Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.EBI Incyte Corporation
18029177 57 A novel series of highly selective inhibitors of MMP-3.EBI Pfizer Global Research and Development
17936631 25 Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.EBI Yonsei University
17591762 102 Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.EBI Pfizer Global Research and Development
17583333 4 Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.EBI Università di Bari
17576061 132 Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17531482 67 Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.EBI Wyeth Research
17512742 32 Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.EBI Université de Reims-Champagne-Ardenne
17433673 44 Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.EBI Shandong University
17428670 1 Inhibitory effect of obovatal on the migration and invasion of HT1080 cells via the inhibition of MMP-2.EBI Korea Research Institute of Bioscience and Biotechnology
17368021 55 Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17276676 112 A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17267227 12 Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.EBI INSERM
17256836 84 Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.EBI Incyte Corporation
17188863 107 Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17088065 106 alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.EBI Università "G. d'Annunzio"
17064892 123 Identification of potent and selective TACE inhibitors via the S1 pocket.EBI Wyeth Research
17027261 153 Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16723229 108 Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.EBI Wyeth Research
16632358 68 Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.EBI Johnson & Johnson Pharmaceutical Research and Development
16516466 175 Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16473009 23 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16420030 38 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.EBI Chinese Academy of Sciences
16392792 29 Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI Aventis Pharma Deutschland GmbH
16289878 35 Conversion of potent MMP inhibitors into selective TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16242329 12 N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.EBI Università degli Studi 'G. d'Annunzio'
16153831 87 Synthesis and SAR of highly selective MMP-13 inhibitors.EBI Wyeth Research
16005220 52 Identification of potent and selective MMP-13 inhibitors.EBI Wyeth Research
16002291 24 Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.EBI Pfizer Global Research and Development
15953722 56 Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.EBI Pfizer Global Research and Development
15908214 95 Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15837315 13 A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.EBI Università degli Studi di Pisa
15780611 74 Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.EBI Pfizer Global Research and Development
15686921 55 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).EBI Pharmaceutical Research Institute
15357971 228 Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15341955 52 Synthesis and evaluation of novel oxazoline MMP inhibitors.EBI North Dakota State University
15324896 71 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.EBI Pfizer Global Research and Development
15163188 12 A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.EBI University of California at San Francisco
15125955 84 Reverse hydroxamate-based selective TACE inhibitors.EBI Kaken Pharmaceutical Co., Ltd
14711305 26 Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI University of Athens
14684295 109 Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.EBI Chinese Academy of Sciences
14643313 129 Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
14643312 39 Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
14611841 8 MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.EBI UMR/CNRS 6013
12877590 28 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI Pfizer Global Research and Development
12877587 6 Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.EBI National Cardiovascular Center Research Institute
12798337 6 Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.EBI Indiana University School of Medicine
12781190 110 Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12729664 14 Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.EBI Université de Reims Champagne-Ardenne
12723945 167 Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12408705 73 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI Bristol-Myers Squibb Company
11754593 148 Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.EBI Abbott Laboratories
11738583 45 Potent P1' biphenylmethyl substituted aggrecanase inhibitors.EBI Bristol-Myers Squibb Pharma Company
11677124 67 Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.EBI Abbott Laboratories
11585440 76 Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI DuPont Pharmaceuticals Company
11585439 44 Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.EBI The DuPont Pharmaceuticals Company
11563922 147 Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.EBI Universität Bielefeld
11551755 18 Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.EBI British Biotech Pharmaceuticals Limited
11543676 45 Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.EBI Université de Montréal
11543675 104 N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.EBI Université de Montréal
11454461 111 The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.EBI Procter and Gamble Pharmaceuticals
11428927 117 A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities.EBI The Royal Danish School of Pharmacy
11412980 48 Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.EBI Abbott Laboratories
11412979 67 Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.EBI Abbott Laboratories
11354379 37 Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.EBI Pfizer Global Research & Development
11327602 58 Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.EBI Roche Research Center
11297453 173 Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.EBI Procter and Gamble Pharmaceuticals
11266157 12 Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement.EBI University of Florida
11229774 40 Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).EBI Pfizer Global Research and Development
11229773 73 Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.EBI Pfizer Global Research and Development
11212095 65 General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.EBI Institut de Recherches Servier
11150165 228 Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.EBI Procter and Gamble Pharmaceuticals
10937713 150 Solid-phase synthesis of an arylsulfone hydroxamate library.EBI Rhone Poulenc Rorer
10882354 19 Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.EBI Pfizer Inc.
10794702 340 Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.EBI Università degli Studi
10639284 119 Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.EBI University of Florida
10522712 109 The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.EBI British Biotech Pharmaceuticals Limited
10522699 37 Design, combinatorial chemical synthesis and in vitro characterization of novel urea based gelatinase inhibitors.EBI University of Wisconsin-Madison
10411481 144 Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI CEA
10346925 40 Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.EBI Shionogi & Company, Ltd.
10052961 24 Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.EBI Rhône-Poulenc Rorer
10021913 42 Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.EBI Pfizer Inc
9873712 109 Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.EBI Abbott Laboratory
9873491 56 The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.EBI Abbott Laboratories
9873367 39 Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.EBI Abbott Laboratories
9599226 25 Macrocyclic amino carboxylates as selective MMP-8 inhibitors.EBI The DuPont Merck Pharmaceutical Co.
9548812 67 Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.EBI Kanebo Ltd.
9484512 130 Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI Shionogi & Co., Ltd.
9457244 189 Matrix metalloproteinase inhibitors: a structure-activity study.EBI Glycomed, Inc.
9191969 31 Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.EBI Institut de Recherche Servier
9083493 95 Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.EBI Merck Research Laboratories
8277511 57 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.EBI Merck Research Laboratories
8064799 16 Cyclic peptides with a phosphinic bond as potent inhibitors of a zinc bacterial collagenase.EBI University of Athens
21524149 13 Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.BDB Suven Life Sciences Ltd
9353361 3 [3H]RY 80: A high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits.BDB National Institute of Diabetes and Digestive and Kidney Diseases
8524985 69 D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.BDB Case Western Reserve University
7680751 48 Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.BDB National Institute of Neurological Disorders and Stroke
7518496 9 Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.BDB Syntex Discovery Research
7515823 54 Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.BDB Novo Nordisk A/S
7509389 8 Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.BDB Fujisawa Pharmaceutical Co. Ltd.
19695884 156 Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.BDB Vernalis (R&D) Ltd
19462975 18 Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.BDB Chemical Genomics Centre of the Max Planck Society
17034127 45 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.BDB University of Newcastle upon Tyne
19345579 14 Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.BDB Wyeth Research
19267461 53 Novel tricyclic inhibitors of IkappaB kinase.BDB Bristol-Myers Squibb Company